(A) Activity of ponatinib against single (black columns) and polymutant (red columns) BCR-ABL1 proteins. (B) The dual mutant T315I/F359V induces a rearrangement of the ABL1 binding pocket that results in weaker ponatinib binding with respect to the unmutated protein.